Dosing corrected for species differences in toxicokinetics using PBPK modelling predicts equivalent reactive metabolite burden following acetaminophen overdose
0 comments.
Click here to read/write comments.
Topics:
Authors: Iain Gardner
Development of a PBPK model for the prediction of Amiodarone pharmacokinetics in fed and fasted state using ADAM model
0 comments.
Click here to read/write comments.
Topics:
Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study
0 comments.
Click here to read/write comments.
Topics:
Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions
0 comments.
Click here to read/write comments.
Topics:
Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole
0 comments.
Click here to read/write comments.
Topics:
Performance Verification and Application of a Cancer population for use in Physiologically Based Pharmacokinetic modelling
0 comments.
Click here to read/write comments.
Topics:
Biokinetic and PBPK modelling to support the rotenone and strobilurin read across case studies (CS4)
0 comments.
Click here to read/write comments.
Topics:
Biokinetic and PBPK Modelling to Support Read-Across Assessment of Repeat Dose and Developmental and Reproductive Toxicity of Valproic Acid Analogues
0 comments.
Click here to read/write comments.
Topics:
Physiologically Based Pharmacokinetic/Pharmacodynamic model of gastrointestinal toxicity induced by 5-fluorouracil in mouse and translation to human
0 comments.
Click here to read/write comments.
Topics:
Development of a Physiologically Based Pharmacokinetic Model of Buspirone and Its Active Metabolite 1-(2-Pyrimidinyl)-Piperazine to Estimate Drug-Drug Interaction and Food Effect
0 comments.
Click here to read/write comments.
Topics:
Prediction of Plasma, Tissue and in vitro Cell Exposure of CS4 Chemicals Using IVIVE-PBPK and Biokinetic Models
0 comments.
Click here to read/write comments.
Topics:
Development of a Mechanistic Model for the PBP/TK Based Prediction of Tissue Exposure Following Inhalation Exposure
0 comments.
Click here to read/write comments.
Topics:
Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A4*22 and/or CYP3A5*3) and a renal transplant population
0 comments.
Click here to read/write comments.
Topics:
In Vitro to In Vivo Extrapolation of Valproic Acid Hepatotoxicity: a Biokinetic and Physiologically Based Toxicokinetic Informed Approach
0 comments.
Click here to read/write comments.
Topics:
Iterative Development of a Physiologically Based Pharmacokinetic Model for Valproic Acid and Reverse Translation of In Vitro Toxicity Data
0 comments.
Click here to read/write comments.
Topics:
Iterative Development and Performance Verification of In Vitro Biokinetic Models
0 comments.
Click here to read/write comments.
Topics:
Lysosomes- falling into a trap of our own making?
0 comments.
Click here to read/write comments.
Topics:
Physiologically-Based Pharmacokinetic Modelling of Cyclosporine A in Rat
0 comments.
Click here to read/write comments.
Topics:
USE OF A PBPK APPROACH TO ASSESS THE RISK OF DRUG INTERACTIONS IN DIABETIC PATIENTS ON POLYPHARMACY TREATMENT REGIMENS
0 comments.
Click here to read/write comments.
Topics:
APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE)
0 comments.
Click here to read/write comments.
Topics: